TACIT BIO INNOVATION LIMITED

Their core work

Tacit Bio Innovation is a UK-based private company engaged in biomedical research, specializing in cancer biology and health-related life sciences. They participate in international researcher exchange networks (MSCA-RISE), contributing industry perspectives to academic collaborations on topics ranging from health microenvironments to RNA-based cancer therapeutics. Their role in these consortia suggests they provide translational or applied research capabilities that complement academic partners, bridging the gap between laboratory science and practical health applications.

What they specialise in

How they've shifted over time

Tacit Bio Innovation started with a broader health and well-being focus — their 2017 CHARMED project explored how green microenvironments affect aging and well-being, touching on health tourism. By 2020, their work shifted decisively toward oncology, with two concurrent projects in cancer monitoring (PRISAR2) and RNA cancer therapeutics (cONCReTE). This pivot from general health sciences to specialized cancer research represents a significant narrowing and deepening of their biomedical focus.

Moving firmly into oncology — particularly non-surgical cancer management and RNA-based treatments — suggesting future collaborations will center on translational cancer research.

How they like to work

Tacit Bio Innovation operates exclusively as a participant, never leading consortia. All three projects are MSCA-RISE (staff exchange) schemes, which typically involve large international networks — their 47 unique partners across 12 countries reflect this. They appear to be a reliable network participant that brings industry-side hosting capacity and applied perspectives to large academic-led researcher mobility projects.

Despite only 3 projects, they have collaborated with 47 unique partners across 12 countries — a direct result of participating in large MSCA-RISE exchange networks. This gives them an unusually wide contact base for a company of their size.

What sets them apart

As a private company participating in MSCA-RISE researcher exchanges, Tacit Bio Innovation occupies an unusual niche — they are an industry host for academic staff mobility in biomedical research, not a typical R&D contractor. Their pivot to oncology (cancer monitoring and RNA therapeutics) combined with their MSCA network gives them connections to research groups that purely commercial entities rarely access. For consortium builders, they offer an industry-side partner familiar with the MSCA-RISE model and embedded in cancer research networks.

Highlights from their portfolio

• cONCReTE
  Their highest-funded project (EUR 119,600) focused on RNA cancer therapeutics — a rapidly growing field with strong commercial potential.
• PRISAR2
  Addresses the clinically significant question of whether proactive monitoring can replace surgery for rectal cancer — a 'watch and wait' approach gaining medical traction.